Compare UEIC & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | APLT |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 38.1M |
| IPO Year | 1993 | 2019 |
| Metric | UEIC | APLT |
|---|---|---|
| Price | $3.23 | $0.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $9.25 | $4.13 |
| AVG Volume (30 Days) | 148.9K | ★ 25.4M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $390,997,000.00 | $1,000,000.00 |
| Revenue This Year | $0.57 | N/A |
| Revenue Next Year | N/A | $5,935.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.35 | N/A |
| 52 Week Low | $2.69 | $0.22 |
| 52 Week High | $12.50 | $2.44 |
| Indicator | UEIC | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 28.15 |
| Support Level | $3.06 | $0.24 |
| Resistance Level | $3.36 | $0.27 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 75.70 | 4.00 |
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.